Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US

Applied Health Economics and Health Policy

Volumn 9, Issue 3, 2011, Pages 197-207

  Davis, Keith L ^a   Bell, Timothy J ^b   Miller, Jacqueline M ^b   Misurski, Derek A ^b   Bapat, Bela ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Adolescents; Children; Cost of illness; Hospitalisation; Infants; Meningococcal infections

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COST OF ILLNESS; DATA BASE; FATALITY; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HOSPITAL COST; HOSPITALIZATION; HUMAN; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MORTALITY; PRESCHOOL CHILD; SCHOOL CHILD; UNITED STATES; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INFANT; LENGTH OF STAY; MALE; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 79955103795     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11587330-000000000-00000     Document Type: Article

References (31)

1. Meredith JR, Galwankar S. Clinical and epidemiological implications ofmeningococcal disease. J Assoc Physicians India 2005; 53: 628-33 (Pubitemid 41280038)
2. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344: 1378-88
3. Centers for Disease Control and Prevention. Prevention and control ofmeningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2005; 54 (RR-07): 1-21
4. Centers for Disease Control and Prevention. Summary of notifiable diseases: United States. MMWR Morb Mortal Wkly Rep 2003; 52: 1-85
5. Rosenstein NE, Perkins BA. Update on Haemophilus influenzae serotype B and meningococcal vaccines. Pediatr Clin North Am 2000; 47: 337-52 (Pubitemid 30179944)
6. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the Uni-ted States, 1998-2007: implications for prevention of me-ningococcal disease. Clin Infect Dis 2010; 50 (2): 184-91
7. Centers for Disease Control and Prevention. Active bacterial core surveillance report: Emerging Infections Program Network-Neisseria meningitidis. 2008 [online]. Available from URL: http://www.cdc.gov/abcs/reports-findings/ survreports/mening08.pdf [Accessed 2010 May 7]
8. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N EnglJ Med 1997; 337: 970-6 (Pubitemid 27425953)
9. Dawson KG, Emerson JC, Burns JL. Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J 1999; 18: 816-22 (Pubitemid 29428539)
10. Centers for Disease Control and Prevention. Active bacterial core surveillance report: Emerging Infections Program Network-Neisseria meningitidis. 2000 [online]. Available from URL: http://www.cdc.gov/abcs/reports-findings/ survreports/mening00.pdf [Accessed 2010 May 7]
11. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ 1993; 42 (2): 21-30
12. Milonovich LM. Meningococcemia: epidemiology, pathophysiology, and management. J Pediatr Health Care 2007; 21 (2): 75-80
13. Black S, Shinefield HR, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumonococcal con-jugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-95
14. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Im-munization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000; 49 (RR-9): 1-35
15. Centers for Disease Control and Prevention. Meningococcal vaccines: what you need to know [online]. Available from URL: http://www.cdc.gov/vaccines/pubs/ vis/downloads/vis-mening.pdf [Accessed 2009 Sep 9]
16. Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10 (5): 317-28
17. O'Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health 2006; 9 (4): 236-42
18. Rancourt C, Gregoire JP, Simons W, et al. Cost-benefit model comparing two alternative immunisation program-mes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years. Pharmacoeconomics 2003; 21 (6): 429-42 (Pubitemid 36461405)
19. Davison KL, Ramsay ME, Crowcroft NS, et al. Estimating the burden of serogroup C meningococcal disease in England and Wales. Commun Dis Public Health 2002; 5 (3): 213-9
20. Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika 1974; 61: 439-47
21. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461-94 (Pubitemid 32515166)
22. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998; 17: 283-95 (Pubitemid 28300217)
23. Long JS. Regression models for categorical and limited dependent variables. Thousand Oaks (CA): Sage Publica-tions, 1997
24. Archer KJ, Lemeshow S, Hosmer DW. Goodness-of-fit tests for logistic regression models when data are collected using a complex sampling design. Comput Stat Data Analy 2007; 51 (9): 4450-64 (Pubitemid 46562535)
25. US Census Bureau. Population estimates [online]. Available from URL: http://www.census.gov/popest/national/asrh/2008-nat-res.html [Accessed 2010 Jan]
26. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vacci-nation catch-up campaign in the United States. Clin Infect Dis 2008; 46 (1): 1-13 (Pubitemid 351263552)
27. O'Brien JA, Patrick AR, Caro JJ. Costs of managing CAP are double for elderly patients. Drug Benefit Trends 2003; 15: 32-47
28. Poland GA. Prevention ofmeningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis 2010; 50: S45-53
29. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vacci-nation programs. Expert Rev Vaccines 2009; 8 (7): 851-61
30. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact ofmeningococcal serogroup C conjugate vaccines on car-riage and herd immunity. J Infect Dis 2008; 197 (5): 737-43 (Pubitemid 351364476)
31. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50: S37-44